The Future of Retina Care: Emerging Treatments and Research
Retinal diseases can affect everyday activities, from reading and driving to recognizing familiar faces. For patients living with conditions like age-related macular degeneration (AMD), diabetic retinopathy, or inherited retinal disorders, advances in research offer new possibilities for protecting their vision. Researchers are working not only to create new treatments, but also to make existing therapies last longer, target disease more precisely, and reduce the burden of ongoing care. Here is a closer look at some of the developments shaping the future of retina treatment, including what’s available now and what’s still being tested.
Treatments Designed to Last Longer
For many retinal conditions, treatment involves regular injections into the eye to control disease activity and protect vision. Although these treatments have helped many patients, frequent appointments can be challenging for people balancing work, family responsibilities, transportation, and other health needs.
One important advancement is with sustained-release drug delivery. These are designed to release medication gradually over time, potentially extending the period between treatments so fewer injections are needed. One investigational treatment is Axpaxli, a hydrogel-based implant that gradually releases a drug called axitinib. In the phase 3 SOL-1 trial, reported by Retinal Physician, 65.9% of patients receiving a single Axpaxli injection maintained their vision at week 52, compared with 44.2% of those receiving aflibercept.
Researchers are also exploring implants, specialized delivery technologies, and other approaches that could maintain therapeutic drug levels for longer periods.
Gene Therapy and Beyond
Gene therapy is another promising area of retinal research. Gene therapy is another promising area of retinal research. Some approaches aim to address the underlying genetic causes of inherited retinal diseases, while others are designed to help retinal cells produce therapeutic proteins, such as anti-VEGF agents. For conditions like wet AMD, researchers are investigating whether these treatments could reduce the need for repeated injections.
Other research explores geographic atrophy, an advanced form of dry AMD that damages areas of the retina and can cause permanent central vision loss. Standard treatments for dry AMD don’t restore lost vision, which is why researchers keep searching for better options, including early-stage gene-based programs. These approaches are still being evaluated, and their safety, effectiveness, and long-term benefits must be demonstrated through clinical research.
New Directions and Retinal Disease Research
Scientists are also studying treatments that target inflammation, protect vulnerable retinal cells, and slow the progression of disease.
For geographic atrophy, two FDA-approved treatments, Syfovre and Izervay, can slow the growth of affected retinal areas in eligible patients. They do not restore retinal cells that have already been lost, and treatment decisions require a discussion of potential benefits and risks with your doctor.
Researchers are also investigating cell-based therapies designed to replace or support damaged retinal cells. Advances in retinal imaging and artificial intelligence may help specialists identify disease changes, monitor treatment response, and make more informed decisions.
Although these developments are encouraging, promising early results do not guarantee that a treatment will become available. Each approach must undergo appropriate testing before its role in patient care is established.
Why Clinical Trials Matter
Every treatment you receive today was once tested in a clinical trial. Clinical trials move through stages, each designed to answer different questions. Is the treatment safe? How well does it work? How long do its effects last? And which patients are most likely to benefit?
That last question matters a lot. A treatment that helps one group of patients may not fit another, and trials help doctors figure out who should get what. Patients interested in research should discuss their diagnosis, treatment history, and goals with their retina specialist. They’ll be able to explain whether an appropriate trial exists and what participation would involve.
Your Next Step
The future of retina care is moving toward treatments that are more targeted, longer-lasting, and better suited to individual patients. While many exciting approaches remain under investigation, established treatments continue to play a vital role in protecting vision today.
At Southeastern Retina Associates, we encourage patients to stay engaged in their eye care and ask questions about new developments. Speak with your retina specialist about the treatments currently available for your condition and whether a clinical trial may be appropriate for you.
If you have concerns about your retinal health or experience changes in your vision, speak with your regular eye doctor about whether a referral to one of our retina specialists may be appropriate. We see patients throughout the region, with retina centers in Chattanooga, Knoxville, the Tri-Cities, and surrounding communities.